Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA

Blood Cancer J. 2017 Sep 15;7(9):e608. doi: 10.1038/bcj.2017.88.

Authors

J-H Liang¹, L Wang¹, R Peter Gale², W Wu¹, Y Xia¹, L Fan¹, J-Y Li¹, W Xu¹

Affiliations

¹ Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
² Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.

No abstract available

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Asparaginase / administration & dosage
DNA, Viral / blood*
Dexamethasone / administration & dosage
Disease-Free Survival
Etoposide / administration & dosage
Female
Herpesvirus 4, Human*
Humans
Lymphoma, Extranodal NK-T-Cell* / blood
Lymphoma, Extranodal NK-T-Cell* / diagnosis
Lymphoma, Extranodal NK-T-Cell* / drug therapy
Lymphoma, Extranodal NK-T-Cell* / mortality
Male
Methotrexate / administration & dosage
Middle Aged
Polyethylene Glycols / administration & dosage
Survival Rate

Substances

DNA, Viral
Polyethylene Glycols
Etoposide
pegaspargase
Dexamethasone
Asparaginase
Methotrexate